Luye Pharma, a China company, has completed three US clinical studies of its investigational version of risperidone, a well-known anti-psychotic drug. Luye encapsulates the active ingredient in microspheres to create an extended release mechanism that requires injections only once every two weeks. Luye expects the three trials, which enrolled a total of 172 patients in the US, will be sufficient for a New Drug filing with the FDA. The drug is also undergoing trials in Europe and Japan.
Help employers find you! Check out all the jobs and post your resume.
